Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases
暂无分享,去创建一个
T. Barbui | P. Guglielmelli | A. Vannucchi | A. Tefferi | N. Gangat | A. Carobbio | S. Betti | F. Farrukh | Valerio DeStefano
[1] G. Ambler,et al. Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis , 2021, The New England journal of medicine.
[2] D. Werring,et al. Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study , 2021, The Lancet.
[3] H. Watson,et al. Clinical observations in patients with cerebral venous sinus thrombosis , 2021, British journal of haematology.
[4] E. Woo,et al. US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021. , 2021, JAMA.
[5] Andreas Greinacher,et al. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination , 2021, The New England journal of medicine.
[6] Fridtjof Lund-Johansen,et al. Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination , 2021, The New England journal of medicine.
[7] Xiaoqin Huang,et al. Clinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients with Essential Thrombocythemia , 2021, Neuropsychiatric disease and treatment.
[8] T. Barbui,et al. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 , 2021, Blood Cancer Journal.
[9] P. Ingrand,et al. Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis? , 2017, Cerebrovascular Diseases.
[10] P. Ingrand,et al. Venous Thrombotic Recurrence After Cerebral Venous Thrombosis: A Long-Term Follow-Up Study , 2017, Stroke.
[11] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[12] T. Barbui,et al. Cerebral vein thrombosis in patients with Philadelphia‐negative myeloproliferative neoplasms An European Leukemia Net study , 2014, American journal of hematology.
[13] W. Ageno,et al. Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases. , 2014, Thrombosis research.
[14] M. Cazzola,et al. The JAK2 V617F mutation in patients with cerebral venous thrombosis , 2012, Journal of thrombosis and haemostasis : JTH.
[15] D. Leys,et al. Risk Score to Predict the Outcome of Patients with Cerebral Vein and Dural Sinus Thrombosis , 2009, Cerebrovascular Diseases.
[16] P. Chiusolo,et al. Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders , 2007, Journal of thrombosis and haemostasis : JTH.
[17] J. Ferro,et al. Prognosis of Cerebral Vein and Dural Sinus Thrombosis: Results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) , 2004, Stroke.